NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 292 filers reported holding NOVOCURE LTD in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $203,716 | -73.2% | 12,614 | -31.2% | 0.00% | -62.5% |
Q2 2023 | $761,320 | -60.5% | 18,345 | -42.7% | 0.01% | -46.7% |
Q1 2023 | $1,924,963 | -2.0% | 32,008 | +19.5% | 0.02% | 0.0% |
Q4 2022 | $1,964,238 | +853.5% | 26,779 | +889.3% | 0.02% | +650.0% |
Q3 2022 | $206,000 | -41.3% | 2,707 | -46.3% | 0.00% | 0.0% |
Q2 2022 | $351,000 | – | 5,045 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 470,884 | $39,681,000 | 20.12% |
HARTLINE INVESTMENT CORP/ | 330,672 | $27,866,000 | 5.97% |
MORGAN JESS S & CO INC | 52,889 | $4,457,000 | 4.37% |
Darsana Capital Partners LP | 1,350,000 | $113,765,000 | 3.88% |
Rhenman & Partners Asset Management AB | 350,000 | $29,495,000 | 3.23% |
COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $843,000 | 2.55% |
Taylor Frigon Capital Management LLC | 38,073 | $3,208,000 | 2.21% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,500 | $2,991,000 | 1.08% |
Granite Investment Partners, LLC | 261,315 | $22,021,000 | 1.04% |
Nicholas Investment Partners, LP | 85,835 | $7,233,000 | 0.74% |